Abbott Laboratories said an analysis of study data showed that its MitraClip system, a heart valve clip designed to reduce mitral regurgitation, had lower rates of major adverse events than surgery. A spokesman for Abbott said the device will be reviewed by an FDA panel later this year, and the company expects to get approval next year.

Related Summaries